Mirikizumab
- Generic Name
- Mirikizumab
- Brand Names
- Omvoh
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1884201-71-1
- Unique Ingredient Identifier
- Z7HVY03PHP
- Background
Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.
...
- Indication
Mirikizumab is indicated for the treatment of adult patients with moderate-to-severely active ulcerative colitis.
- Associated Conditions
- Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
Association Between Effectiveness of Mirikizumab and UC Patients with High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Showa Inan General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06626165
- Locations
- 🇯🇵
Showa Inan General Hospital, Komagane, Nagano, Japan
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT06598943
- Locations
- 🇺🇸
Southern California Research Center, Inc., Coronado, California, United States
🇺🇸Southern California GI and Liver Centers (SCLC), Coronado, California, United States
🇺🇸Orlando Health Digestive Health Institute, Orlando, Florida, United States
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 160
- Registration Number
- NCT05767021
- Locations
- 🇺🇸
Advanced Research Associates, LLC, Miami, Florida, United States
🇺🇸Gastroenterology Research of San Antonio, San Antonio, Texas, United States
🇺🇸Southern Star Research Institute, LLC, San Antonio, Texas, United States
A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 456
- Registration Number
- NCT05644353
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸Qps-Mra, Llc, Miami, Florida, United States
A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 396
- Registration Number
- NCT05515601
- Locations
- 🇺🇸
Labcorp Clinical Research LP, Dallas, Texas, United States
🇺🇸Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸QPS, Springfield, Missouri, United States
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT05509777
- Locations
- 🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States
🇮🇱Hadassah University Hospital, Ein Kerem,, Jerusalem, Israel
🇯🇵National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Conditions
- Interventions
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 150
- Registration Number
- NCT04844606
- Locations
- 🇺🇸
Children's Center for Digestive Health Care, LLC, Atlanta, Georgia, United States
🇮🇱Yitzhak Shamir Medical Center, Zerifin, HaMerkaz, Israel
🇮🇱Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel
A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT04548219
- Locations
- 🇺🇸
QPS, Springfield, Missouri, United States
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 778
- Registration Number
- NCT04232553
- Locations
- 🇺🇸
Digestive Health Specialists, Dothan, Alabama, United States
🇺🇸Research Solutions of Arizona, Litchfield Park, Arizona, United States
🇺🇸Arizona Arthritis & Rheumatology Associates, Phoenix, Arizona, United States
A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT04004611
- Locations
- 🇺🇸
Childrens Hospital of Orange County, Orange, California, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Riley Hospital for Children, Carmel, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.